Wang X, et al. - The current study's goal was to evaluate whether older, Asian or severely affected patients with acute ischemic stroke (AIS) who were considered at high risk of thrombolysis could benefit more from low-dose rather than standard-dose alteplase treatment. The clinicians found that in key demographic subgroups of patients with AIS, the effects of low-dose alteplase were not clearly superior to the effects of standard-dose alteplase on death or disability. To identify patients with AIS who could benefit from low-dose alteplase, additional research was needed.